Medline Inc. 10-Q Summary: Q1 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 28, 2026. Medline Inc. is a holding company and the largest provider of medical-surgical products and supply chain solutions. The company operates through two segments: Medline Brand (manufacturing and procurement) and Supply Chain Solutions (distribution of third-party products). The quarter followed the company's Initial Public Offering (IPO) in December 2025 and a secondary offering by selling stockholders in March 2026.
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Sales | $7,352 | $6,644 |
| Gross Profit | $1,841 | $1,824 |
| Gross Margin | 25.0% | 27.5% |
| Operating Income | $422 | $571 |
| Net Income | $239 | $322 |
| Net Income Attributable to Medline Inc. | $129 | $322 |
| Diluted EPS (Class A) | $0.16 | N/A |
| Adjusted EBITDA | $776 | $868 |
| Operating Cash Flow | $412 | $682 |
| Total Debt | $12,755 | N/A |
| Cash and Equivalents | $2,236 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 10.7% to $7.35 billion, driven primarily by volume growth in Prime Vendor relationships. U.S. sales grew 10.7%, while International sales grew 10.0%.
- Margin Compression: Gross margin declined to 25.0% from 27.5%. Management attributed this to higher import costs due to tariffs (approx. $120 million impact on pre-tax income) and lower-margin sales to new Prime Vendor customers.
- Operating Expenses: SG&A expenses rose 14.8% to $1.23 billion, driven by increased headcount, distribution costs, and one-time IPO-related bonuses ($18 million).
- Interest Expense: Net interest expense decreased 35.2% to $136 million due to the repayment of Euro Term Loans and a portion of Dollar Term Loans using IPO proceeds, alongside lower variable interest rates.
- Tax Provision: The effective tax rate increased to 17.72% from 4.81% due to the Reorganization, which subjected a greater portion of earnings to corporate-level U.S. federal and state taxes.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates a net negative impact of approximately $120 million on income before taxes for Q1 2026 due to tariffs. The full-year impact remains uncertain depending on policy changes and mitigation efforts.
- Geopolitical Risks: Ongoing conflicts in the Middle East and Ukraine pose risks to energy supplies, inflation, and global supply chains.
- Liquidity: The company maintains $2.24 billion in cash and $946 million in available revolver capacity. Capital expenditures for 2026 are projected at approximately $500 million.
- Tax Receivable Agreement (TRA): A liability of $4.02 billion was recorded as of March 28, 2026, increasing by $479 million due to the March 2026 Resale Offering. This agreement requires the company to pay 90% of certain tax benefits to pre-IPO owners.
- Legal Proceedings: The company is finalizing a settlement regarding hazardous waste management in California (approx. $0.9 million) and continues to pursue litigation with insurance carriers regarding ethylene oxide settlement costs.
Investor Verification Checklist
- Tariff Mitigation: Verify the specific strategies and success rate of re-allocating production and sourcing to offset the $120 million tariff impact.
- Prime Vendor Margins: Monitor the margin trajectory of new Prime Vendor customers to ensure they do not permanently depress overall gross margins.
- TRA Liability: Track the growth of the Tax Receivable Agreement liability and its impact on future cash flows and distributions to noncontrolling interests.
- Debt Covenants: Confirm continued compliance with the springing financial covenant (8.3x leverage ratio) on the Revolving Credit Facility, though currently not tested due to low revolver usage.
- Noncontrolling Interest: Observe the reduction in noncontrolling interest following the March 2026 Resale Offering and its effect on net income attributable to Medline Inc.